globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
Company profile
Ticker
GMED
Exchange
Website
CEO
David Demski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Globus Medical North America, Inc. • Branch Medical Group, LLC • NuVasive, Inc. • NuVasive Technology International Limited • KB Medical SA • Nemaris Inc. • Globus Medical SARL • MIS Spine Comercials de R.L. de C.V. • NuVasive Netherlands B.V. • NuVasive Clinical Services Monitoring Inc. ...
IRS number
43744954
GMED stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Globus Medical Reports First Quarter 2024 Results
7 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Globus Medical Reports Fourth Quarter and Full Year 2023 Results
20 Feb 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
8-K
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
10 Jan 24
S-8
Registration of securities for employees
30 Nov 23
Transcripts
GMED
Earnings call transcript
2024 Q1
7 May 24
GMED
Earnings call transcript
2023 Q4
20 Feb 24
GMED
Earnings call transcript
2023 Q3
7 Nov 23
GMED
Earnings call transcript
2023 Q2
3 Aug 23
GMED
Earnings call transcript
2023 Q2
3 Aug 23
GMED
Earnings call transcript
2023 Q1
4 May 23
GMED
Earnings call transcript
2022 Q4
21 Feb 23
GMED
Earnings call transcript
2022 Q3
9 Nov 22
GMED
Earnings call transcript
2022 Q2
5 Aug 22
GMED
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
4
Dan Lemaitre
14 May 24
4
David D Davidar
10 May 24
144
Notice of proposed sale of securities
10 May 24
144
Notice of proposed sale of securities
10 May 24
144
Notice of proposed sale of securities
8 May 24
144
Notice of proposed sale of securities
8 May 24
4
Leslie V Norwalk
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Kelly Huller
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 354.06 mm | 354.06 mm | 354.06 mm | 354.06 mm | 354.06 mm | 354.06 mm |
Cash burn (monthly) | 37.74 mm | (no burn) | 2.85 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 78.00 mm | n/a | 5.90 mm | n/a | n/a | n/a |
Cash remaining | 276.06 mm | n/a | 348.17 mm | n/a | n/a | n/a |
Runway (months of cash) | 7.3 | n/a | 122.0 | n/a | n/a | n/a |
Institutional ownership, Q1 2024
18.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 195 |
Opened positions | 43 |
Closed positions | 163 |
Increased positions | 52 |
Reduced positions | 59 |
13F shares | Current |
---|---|
Total value | 934.76 bn |
Total shares | 21.06 mm |
Total puts | 18.90 k |
Total calls | 103.30 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BK Bank Of New York Mellon | 3.02 mm | $161.82 bn |
William Blair Investment Management | 2.24 mm | $119.99 bn |
GW&K Investment Management | 1.75 mm | $93.69 mm |
Geneva Capital Management | 1.57 mm | $84.32 bn |
Vaughan Nelson Investment Management | 964.09 k | $51.71 mm |
Global Alpha Capital Management | 927.74 k | $49.76 bn |
Motley Fool Asset Management | 848.16 k | $45.50 bn |
Allspring Global Investments | 803.11 k | $43.08 bn |
Boston Trust Walden | 748.74 k | $40.16 bn |
Paradice Investment Management | 641.06 k | $34.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 May 24 | Dan Lemaitre | Class A Common Stock | Sell | Dispose S | No | No | 64.6133 | 63,300 | 4.09 mm | 0 |
10 May 24 | Dan Lemaitre | Class A Common Stock | Option exercise | Acquire M | No | No | 53.27 | 17,500 | 932.23 k | 63,300 |
10 May 24 | Dan Lemaitre | Class A Common Stock | Option exercise | Acquire M | No | No | 43.58 | 17,500 | 762.65 k | 45,800 |
10 May 24 | Dan Lemaitre | Class A Common Stock | Option exercise | Acquire M | No | No | 43.77 | 17,500 | 765.98 k | 28,300 |
10 May 24 | Dan Lemaitre | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Option exercise | Dispose M | No | No | 53.27 | 17,500 | 932.23 k | 0 |
10 May 24 | Dan Lemaitre | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Option exercise | Dispose M | No | No | 43.58 | 17,500 | 762.65 k | 0 |
10 May 24 | Dan Lemaitre | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Option exercise | Dispose M | No | No | 43.77 | 17,500 | 765.98 k | 0 |
8 May 24 | David D Davidar | Class A Common Stock | Sell | Dispose S | No | Yes | 65 | 20,000 | 1.30 mm | 566,275 |
15 Mar 24 | Norwalk Leslie V | Class A Common Stock | Sell | Dispose S | No | Yes | 51.99 | 10,590 | 550.57 k | 17,419 |
1 Mar 24 | Huller Kelly | Class A Common Stock | Sell | Dispose S | No | Yes | 54.53 | 3,115 | 169.86 k | 0 |
News
Deep Dive Into Globus Medical Stock: Analyst Perspectives (7 Ratings)
29 May 24
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
29 May 24
BTIG Maintains Buy on Globus Medical, Raises Price Target to $72
29 May 24
This Micron Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Today
20 May 24
Piper Sandler Upgrades Globus Medical to Overweight, Raises Price Target to $80
20 May 24